Logo image of PODD

INSULET CORP (PODD) Stock Price, Forecast & Analysis

USA - NASDAQ:PODD - US45784P1012 - Common Stock

319.82 USD
-3.58 (-1.11%)
Last: 11/7/2025, 8:09:04 PM
319.82 USD
0 (0%)
After Hours: 11/7/2025, 8:09:04 PM

PODD Key Statistics, Chart & Performance

Key Statistics
Market Cap22.51B
Revenue(TTM)2.52B
Net Income(TTM)236.10M
Shares70.39M
Float70.12M
52 Week High353.5
52 Week Low230.05
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)4.57
PE69.98
Fwd PE54
Earnings (Next)02-18 2026-02-18/amc
IPO2007-05-15
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment


PODD short term performance overview.The bars show the price performance of PODD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 1 2 3 4

PODD long term performance overview.The bars show the price performance of PODD in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60

The current stock price of PODD is 319.82 USD. In the past month the price increased by 1.69%. In the past year, price increased by 19.34%.

INSULET CORP / PODD Daily stock chart

PODD Latest News, Press Relases and Analysis

PODD Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES25.32219.92B
ISRG INTUITIVE SURGICAL INC65.04200.75B
BSX BOSTON SCIENTIFIC CORP33.91148.20B
SYK STRYKER CORP27.03136.11B
IDXX IDEXX LABORATORIES INC56.1856.68B
BDX BECTON DICKINSON AND CO12.3350.97B
EW EDWARDS LIFESCIENCES CORP32.4548.96B
RMD RESMED INC25.436.70B
GEHC GE HEALTHCARE TECHNOLOGY15.9233.35B
DXCM DEXCOM INC29.5721.57B
ZBH ZIMMER BIOMET HOLDINGS INC10.9417.53B
HOLX HOLOGIC INC17.3516.48B

About PODD

Company Profile

PODD logo image Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts and currently employs 3,900 full-time employees. The company went IPO on 2007-05-15. The company is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. The company also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.

Company Info

INSULET CORP

100 Nagog Park

Acton MASSACHUSETTS 01720 US

CEO: Shacey Petrovic

Employees: 3900

PODD Company Website

PODD Investor Relations

Phone: 19786007000

INSULET CORP / PODD FAQ

Can you describe the business of INSULET CORP?

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts and currently employs 3,900 full-time employees. The company went IPO on 2007-05-15. The company is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. The company also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.


What is the stock price of INSULET CORP today?

The current stock price of PODD is 319.82 USD. The price decreased by -1.11% in the last trading session.


What is the dividend status of INSULET CORP?

PODD does not pay a dividend.


How is the ChartMill rating for INSULET CORP?

PODD has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 7 out of 10.


On which exchange is PODD stock listed?

PODD stock is listed on the Nasdaq exchange.


How is the valuation of INSULET CORP (PODD) based on its PE ratio?

The PE ratio for INSULET CORP (PODD) is 69.98. This is based on the reported non-GAAP earnings per share of 4.57 and the current share price of 319.82 USD.


What is the market capitalization of PODD stock?

INSULET CORP (PODD) has a market capitalization of 22.51B USD. This makes PODD a Large Cap stock.


PODD Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to PODD. When comparing the yearly performance of all stocks, PODD is one of the better performing stocks in the market, outperforming 75.93% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

PODD Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to PODD. PODD scores excellent on profitability, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PODD Financial Highlights

Over the last trailing twelve months PODD reported a non-GAAP Earnings per Share(EPS) of 4.57. The EPS increased by 27.65% compared to the year before.


Industry RankSector Rank
PM (TTM) 10.01%
ROA 6.81%
ROE 16.14%
Debt/Equity 0.64
Chartmill High Growth Momentum
EPS Q2Q%37.78%
Sales Q2Q%29.86%
EPS 1Y (TTM)27.65%
Revenue 1Y (TTM)27.12%

PODD Forecast & Estimates

33 analysts have analysed PODD and the average price target is 367.77 USD. This implies a price increase of 14.99% is expected in the next year compared to the current price of 319.82.

For the next year, analysts expect an EPS growth of 42.69% and a revenue growth 27.75% for PODD


Analysts
Analysts85.45
Price Target367.77 (14.99%)
EPS Next Y42.69%
Revenue Next Year27.75%

PODD Ownership

Ownership
Inst Owners101.85%
Ins Owners0.27%
Short Float %2.3%
Short Ratio2.82